Progression in Parkinson's disease: A positron emission tomography study with a dopamine transporter ligand [18F]CFT

Nurmi, Elina; Ruottinen, Hanna; Kaasinen, Valtteri; Bergman, Jörgen; Haaparanta, Merja; Solin, Olof; Rinne, J. O.

doi:10.1002/1531-8249(200006)47:6<804::aid-ana14>3.0.co;2-f

Cited by 156 publications

(42 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…[14][15][16] UPDRS scores at baseline were considerably lower in SWEDD subjects compared with DAT deficit subjects, and there was no change in UPDRS scores during the 22-month follow-up in SWEDD subjects, compared with an increase in DAT deficit subjects consistent with other clinical studies of newly diagnosed PD. 2,[17][18][19] Subjects with a baseline SWEDD showed an equal sex distribution, rather than the expected male predominance in PD evident in most PD clinical studies.…”

Section: Resultssupporting

confidence: 87%

Longitudinal follow-up of SWEDD subjects in the PRECEPT Study

et al. 2014

View full text Add to dashboard Cite

Objective: To compare the clinical and imaging characteristics of those PRECEPT (Parkinson Research Examination of CEP-1347 Trial) subjects with a scan without evidence of dopaminergic deficit (SWEDD) to those with dopamine transporter (DAT) deficit scans at study baseline and during a 22-month follow-up.Methods: Baseline (n 5 799) and 22-month follow-up (n 5 701) [123 I] b-CIT SPECT scans were acquired. The percent change in [123 I] b-CIT striatal binding ratio, the percentage of subjects requiring dopaminergic therapy, the change in Unified Parkinson's Disease Rating Scale (UPDRS) score, and the PRECEPT Study investigators' diagnosis at study termination were compared between SWEDD and DAT deficit subjects.Results: SWEDD subjects (n 5 91) compared with DAT deficit subjects (n 5 708) showed reduced .9], p , 0.0001) at follow-up assessments. At PRECEPT termination, the diagnosis by study investigators was changed from Parkinson disease (PD) to other disorders not associated with DAT deficit in 44% (95% confidence interval 34.2, 54.7) of SWEDD subjects compared with 3.6% (95% confidence interval 2.3, 5.1) of DAT deficit subjects. Conclusion:These results indicate that subjects identified as having a SWEDD, with DAT imaging within the normal range, have minimal evidence of clinical or imaging PD progression. These data strongly suggest that SWEDD subjects are unlikely to have idiopathic PD. In several recent Parkinson disease (PD) clinical trials, dopaminergic imaging has been used as a tool to assess PD progression. Both dopamine transporter (DAT) SPECT and [ 18 F] fluoro-Ldopa PET imaging identified research subjects having a scan without evidence of dopaminergic deficit (SWEDD) enrolled in PD clinical trials of newly diagnosed untreated patients. [1][2][3][4] In PD studies enrolling participants within 9 months of PD diagnosis, approximately 10% to 15% of the research subjects have a SWEDD. Longitudinal assessment has demonstrated that those subjects with a SWEDD at baseline continue to have a SWEDD in follow-up scans for at least a 4-year period. 5The Parkinson Research Examination of CEP-1347 Trial (PRECEPT) was a multicenter, randomized, double-masked, placebo-controlled study to examine the efficacy and long-term safety of CEP-1347 as a potential disease-modifying treatment in patients with early PD.

show abstract

Section: Resultssupporting

confidence: 87%

Longitudinal follow-up of SWEDD subjects in the PRECEPT Study

et al. 2014

View full text Add to dashboard Cite

show abstract

“…[47][48][49] In early PD patients treated with L-dopa putamen, 18 F-dopa uptake has been reported to decline annually by around 10% of baseline (5% of the normal mean), whereas caudate uptake falls at a slower rate. Similar rates of loss of putamen dopamine transporter binding have been reported with 18 F-CFT PET 50 and with 123 I-␤-CIT, 51 123 I-FP-CIT, 52 and 123 I-IPT SPECT. 53 …”

Section: Monitoring Pd Progressionsupporting

confidence: 77%

Neuroimaging in Parkinson’s disease

Brooks

2004

Neurotherapeutics

View full text Add to dashboard Cite

Summary:In this review, the potential role of positron emission tomography and single photon emission computed tomography as biological markers for diagnosing and following the progression of Parkinson's disease (PD) is discussed. Their value for assessing the efficacy of putative neuroprotective agents in PD and for revealing the pharmacological changes underlying the symptomatology and complications of this disorder is also considered. It is concluded that in the future functional imaging will provide a valuable adjunct to clinical assessment when judging the efficacy of putative neuroprotective approaches to PD.

show abstract

“…18 F]CFT as a radiotracer for the dopamine transporter, showed that the rate of annual decline in early PD patients, was 13,1% and 12,5% in the putamen and caudate nucleus, respectively (Nurmi et al, 2000). In addition, several [ 18 F]DOPA PET studies showed progression of disease in PD (Vingerhoets et al, 1994;Morrish et al, 1996Morrish et al, , 1998.…”

Section: Resultsmentioning

confidence: 99%

[ 123 I]FP-CIT SPECT is a useful method to monitor the rate of dopaminergic degeneration in early-stage Parkinson's disease

Winogrodzka

Bergmans

Booij

et al. 2001

Journal of Neural Transmission

View full text Add to dashboard Cite

Disclaimer/Complaints regulationsIf you believe that digital publication of certain material infringes any of your rights or (privacy) interests, please let the Library know, stating your reasons. In case of a legitimate complaint, the Library will make the material inaccessible and/or remove it from the website. Please Ask the Library: http://uba.uva.nl/en/contact, or a letter to: Library of the University of Amsterdam, Secretariat, Singel 425, 1012 WP Amsterdam, The Netherlands. You will be contacted as soon as possible. Summary. We investigated the applicability [ 123 I]FP-CIT SPECT for the assessment of the rate of dopaminergic degeneration in PD.Twenty early-stage PD patients (age range 43-73 yr; mean age 55.4) were examined twice, a mean of 12 months apart. The mean annual change in the ratio of specific to nonspecific [ In order to demonstrate a significant effect (p Ͻ 0.05) of putative neuroprotective agent with 0.80 power and 50% of predicted protection within 2 years, 36 patients are required in each group, when the effects are measured by means of changes in [123 I]FP-CIT binding ratios in whole striatum. Our findings indicate that [123 I]FP-CIT SPECT seems to be a useful tool to investigate the progression of dopaminergic degeneration in PD and may provide an objective method of measuring the effectiveness of neuroprotective therapies.

show abstract

Progression in Parkinson's disease: A positron emission tomography study with a dopamine transporter ligand [18F]CFT

Cited by 156 publications

References 21 publications

Longitudinal follow-up of SWEDD subjects in the PRECEPT Study

Longitudinal follow-up of SWEDD subjects in the PRECEPT Study

Neuroimaging in Parkinson’s disease

[ 123 I]FP-CIT SPECT is a useful method to monitor the rate of dopaminergic degeneration in early-stage Parkinson's disease

Contact Info

Product

Resources

About